Corcept Therapeutics (CORT) Price & Analysis

Compare

1,291 Followers

CORT Stock Chart & Stats

$34.64

$0.08(0.16%)

At close: Jan 08 4:00 PM EST

$34.64

$0.08(0.16%)

Day’s Range― - ―

52-Week Range$28.66 - $117.33

Previous CloseN/A

Volume78.39K

Average Volume (3M)1.59M

Market Cap

$3.68B

Enterprise Value$3.57B

Total Cash (Recent Filing)$372.15M

Total Debt (Recent Filing)$6.11M

Price to Earnings (P/E)36.3

Beta0.47

Next Earnings

May 06, 2026

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.20

Shares Outstanding106,374,020

10 Day Avg. Volume1,148,825

30 Day Avg. Volume1,592,083

Financial Highlights & Ratios

PEG Ratio-1.22

Price to Book (P/B)5.58

Price to Sales (P/S)4.75

P/FCF Ratio25.49

Enterprise Value/Market Cap0.97

Enterprise Value/Revenue4.69

Enterprise Value/Gross Profit4.77

Enterprise Value/Ebitda62.49

Forecast

1Y Price Target

$93.67

Price Target Upside170.41% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)0.36

Revenue Forecast (FY)$884.48M

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And Label ExpansionPivotal trial results showing a survival benefit for relacorilant plus chemotherapy across patient subgroups support broader adoption and the potential to test the drug in additional gynecologic cancers, expanding the addressable market.

Distribution And SupplyResolution of prior specialty pharmacy supply issues and improved prescription‑filling efficiency could restore Korlym sales momentum and remove a major headwind to revenue.

Regulatory Approval OpportunityFDA review with a PDUFA date in July 2026 and a favorable probability of approval could enable initial commercial sales of relacorilant for platinum‑resistant ovarian cancer and materially boost revenue.

Bears Say

Generic Competition And Pricing PressureCourt rulings limiting patent protection combined with rising use of lower‑priced authorized generics raise the risk of price erosion and reduced revenue per prescription for Korlym.

Regulatory Uncertainty And Trial DelaysA Complete Response Letter that likely requires additional confirmatory trials could delay relacorilant's market entry by multiple years and weaken near‑term valuation prospects.

Revenue ConcentrationHeavy dependence on Korlym as the company's sole revenue‑generating product increases vulnerability to sales disruptions, competitive entries, and any decline in prescription volumes.

Corcept Therapeutics News

Corcept Therapeutics director buys $3.3M in common stock

In a regulatory filing, Corcept Therapeutics (CORT) disclosed that its director Leonard Baker bought 100K shares of common...

4d ago

CORT

Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Corcept Therapeutics (CORT) to $60 from $67...

26d ago

CORT

Corcept Therapeutics reports Q4 EPS 20c, consensus 33c

Reports Q4 revenue $202.1M, consensus $254.94M. “In 2025, our Cushing’s syndrome business experienced a surge in demand due...

26d ago

CORT

Corcept Therapeutics Lawsuit: CORT Investors Face Losses After FDA Rejection and Alleged Misleading Statements

Corcept Therapeutics ($CORT) told investors relacorilant was a promising next-generation treatment for hypercortisolism supported by clinical data and...

11d ago

CORT

Corcept Therapeutics Balances Growth With Rising Risks

Corcept Therapeutics (($CORT)) has held its Q4 earnings call. Read on for the main highlights of the call....

25d ago

CORT

Corcept Therapeutics Posts Strong 2025 Results, Issues Optimistic Outlook

Corcept Therapeutics ( ($CORT) ) has provided an update. On February 24, 2026, Corcept Therapeutics reported audited fourth-quarter...

27d ago

CORT

Corcept Therapeutics price target lowered to $67 from $105 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Corcept Therapeutics (CORT) to $67 from $105 and keeps a...

1M ago

CORT

TEVA

Corcept Faces Appellate Setback in Korlym Patent Dispute

Corcept Therapeutics ( ($CORT) ) just unveiled an update. On February 19, 2026, Corcept Therapeutics announced that the...

1M ago

CORT

Corcept ‘disappointed’ in court ruling over Teva patent dispute

Corcept Therapeutics Incorporated (CORT) announced that the United States Court of Appeals for the Federal Circuit has found...

1M ago

CORT

TEVA

Midday Fly By: Walmart reports Q4 beat, eBay to acquire Depop from Etsy

The major averages were lower near noon, giving back some of the gains from Wednesday as investors respond...

1M ago

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

TipRanks provides a list of the hottest stock market stories in our daily wrap-up for Thursday. ...

1M ago

Corcept Therapeutics Stock Crashes 21% after Patent Defeat to Teva

Biopharma firm Corcept Therapeutics’ ($CORT) shares took a massive beating on Thursday morning. This came after a U.S....

1M ago

CORT

TEVA

Corcept Therapeutics down 18% after appeals court ruling in Teva fight

Shares of Corcept Therapeutics (CORT) have fallen $7.19, or 18%, to $32.63 in morning trading after the United...

1M ago

CORT

TEVA

Corcept Therapeutics trading resumes

10:31 EST Corcept Therapeutics (CORT) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

1M ago

CORT

CORT FAQ

What was Corcept Therapeutics Inc.’s price range in the past 12 months?

Corcept Therapeutics Inc. lowest stock price was $28.66 and its highest was $117.33 in the past 12 months.

What is Corcept Therapeutics Inc.’s market cap?

Corcept Therapeutics Inc.’s market cap is $3.68B.

When is Corcept Therapeutics Inc.’s upcoming earnings report date?

Corcept Therapeutics Inc.’s upcoming earnings report date is May 06, 2026 which is in 44 days.

How were Corcept Therapeutics Inc.’s earnings last quarter?

Corcept Therapeutics Inc. released its earnings results on Feb 24, 2026. The company reported $0.2 earnings per share for the quarter, missing the consensus estimate of $0.329 by -$0.129.

Is Corcept Therapeutics Inc. overvalued?

According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corcept Therapeutics Inc. pay dividends?

Corcept Therapeutics Inc. does not currently pay dividends.

What is Corcept Therapeutics Inc.’s EPS estimate?

Corcept Therapeutics Inc.’s EPS estimate is -0.11.

How many shares outstanding does Corcept Therapeutics Inc. have?

Corcept Therapeutics Inc. has 106,374,020 shares outstanding.

What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?

Corcept Therapeutics Inc. reported an EPS of $0.2 in its last earnings report, missing expectations of $0.329. Following the earnings report the stock price went down -0.713%.

Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?

Currently, no hedge funds are holding shares in CORT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Corcept Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

15.25%

Trailing 12-Months

Asset Growth

-0.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corcept Therapeutics Inc.

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics (CORT) Earnings & Revenues

Historic Earnings Reports

CORT Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call presented a mix of strong commercial momentum, robust clinical successes across multiple programs (notably ROSELLA and DAZALS), clear revenue growth and higher guidance, and resolved operational capacity with an improving commercial outlook. These positives are tempered by a significant regulatory setback for relacorilant in Cushing's syndrome, a Federal Circuit loss in the generic patent dispute, meaningful net income decline, and prior pharmacy-related supply disruptions. The pipeline and upcoming readouts provide multiple near-term catalysts, while regulatory and legal risks require attention.View all CORT earnings summaries

CORT Stock 12 Month Forecast

Average Price Target

$93.67

▲(170.41% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"$33","122":"$122","55.25":"$55.3","77.5":"$77.5","99.75":"$99.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":121,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$121.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,55.25,77.5,99.75,122],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.97,42.51076923076923,49.051538461538456,55.59230769230769,62.13307692307692,68.67384615384614,75.21461538461539,81.75538461538461,88.29615384615384,94.83692307692307,101.3776923076923,107.91846153846153,114.45923076923077,{"y":121,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.97,40.40846153846154,44.846923076923076,49.285384615384615,53.723846153846154,58.16230769230769,62.60076923076923,67.03923076923077,71.47769230769231,75.91615384615385,80.35461538461539,84.79307692307692,89.23153846153846,{"y":93.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,35.97,37.818461538461534,39.66692307692308,41.51538461538461,43.363846153846154,45.21230769230769,47.06076923076923,48.90923076923077,50.75769230769231,52.606153846153845,54.45461538461538,56.30307692307692,58.151538461538465,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":60.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.93,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.47,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.97,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 52, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >